NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel group, Phase 3 trial to
evaluate the safety and efficacy of NT0102 in the treatment of Attention Deficit
Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age in a laboratory
classroom study.